Asahi Kasei Offers $1.1B for Swedish Pharma Calliditas Therapeutics 5/28/2024

AstraZeneca, Daiichi Sankyo ADC Misses Endpoint in Phase III NSCLC Study 5/28/2024

NS Pharma’s DMD Candidate Viltespo Fails Confirmatory Phase III Trial 5/28/2024

Novo Nordisk’s Once-Weekly Insulin Loses FDA Adcomm Vote for Type 1 Diabetes 5/28/2024

Novartis Eyes Rare Kidney Disease Approvals on Heels of Two Phase III Wins 5/28/2024

30 Years After Genetic Discovery, Huntington’s Patients Still Waiting 5/28/2024

Despite Progress, ADCs Still Stalled in Non-Small Cell Lung Cancer 5/28/2024

Precision Medicine and Novel Approaches on Cusp of Breaking Through in Psychiatry 5/28/2024

Opinion: How to Make Today’s Clinical Research More Efficient 5/28/2024

Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development lifecycle. This represents a first collaboration of its kind within the pharma and life sciences industries.

Public interest in weight loss drugs like Wegovy and Ozempic is surging, but national data on dispensing patterns in the United States are surprisingly scarce.

Now, a national study from Michigan Medicine shows that the use of these weight loss drugs is increasing rapidly in adolescents and young adults 12-25 years, especially females.

Lilly Invests Another $5.3B in Indiana Plant to Boost Tirzepatide Manufacturing 5/24/2024

Novo Nordisk’s Semaglutide Cuts Death Risk in Diabetics with CKD in Phase III Trial 5/24/2024

ASCO24: J&J Reports Four Patient Deaths in Early-Stage Prostate Cancer Trial 5/24/2024

ASCO24: Regeneron’s Bispecific Antibody Falls Flat in Early Study 5/24/2024

Is AstraZeneca’s $80B Revenue Goal By 2030 a Bridge Too Far? 5/24/2024

ASCO24: Nimbus Plots Path for Next-Gen IO Therapies with Strong Early HPK1 Blocker Data 5/24/2024

Zealand Touts Phase I Results for GLP-1, GLP-2 Candidate Despite Modest Weight Loss 5/24/2024

Regular use of fish oil supplements might increase, rather than lessen, the risk of first time heart disease and stroke among those in good cardiovascular health, but may slow progression of existing poor cardiovascular health and lower the risk of death, suggest the results of a large long term study, published in the open access journal BMJ Medicine.

Fish oil is a rich source of omega 3 fatty acids, and as such, is recommended as a dietary preventive to ward off the development of cardiovascular disease.

Takeda Joins Hot Molecular Glue Market With $1.2B Deal 5/23/2024